Uncovers HIF's involvement in cell cycle progression in hepatocellular carcinoma, suggesting new therapeutic targets.
Hepatocellular carcinoma (HCC) remains one of the most lethal malignancies worldwide, largely due to late diagnosis and limited therapeutic options. Tumor hypoxia is a hallmark of HCC and drives aggressive disease behavior, in part through activation of hypoxia‐inducible factors (HIFs). While HIF‐1α is classically understood as a hypoxia‐responsive transcription factor, its role under normoxic conditions in cells is less clear. The study presented by Gkotinakou and colleagues in this issue provides important insight into this question by revealing a previously underappreciated dependence of HIF‐1 signaling in controlling cell cycle progression in HCC, even in the presence of normal oxygen levels.
No takes yet. Share an insight, caveat, or question.
Kenneth et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: